```html

Autoimmune Hemolytic Anemia (AIHA) – A Patient‑Friendly Medical Guide

Overview

Autoimmune hemolytic anemia (AIHA) is a rare disorder in which the immune system mistakenly produces antibodies that bind to the patient’s own red blood cells (RBCs), leading to their premature destruction (hemolysis). The resulting anemia can range from mild fatigue to life‑threatening low blood‑cell counts.

• Who it affects: AIHA can occur at any age but shows a bimodal pattern – a peak in children (particularly 2‑5 years) and another in adults aged 50‑70 years. Women are slightly more often affected than men (approximately 55 % vs. 45 %).
• Prevalence: The overall incidence is about 1‑3 cases per 100,000 people per year in the United States and Europe. Warm AIHA (the most common type) accounts for roughly 70‑80 % of cases, while cold agglutinin disease (CAD) comprises the remaining 20‑30 %<sup>1</sup>.

Symptoms

Symptoms arise from anemia, hemolysis, and sometimes from the underlying condition that triggered the autoimmunity. They can develop slowly or abruptly.

General anemia‑related symptoms

• Fatigue & weakness – due to reduced oxygen delivery.
• Shortness of breath – especially on exertion.
• Pale or yellowish skin (pallor, jaundice).
• Rapid heartbeat (tachycardia) or palpitations.
• Dizziness or light‑headedness, particularly when standing.
• Headaches or difficulty concentrating.

Hemolysis‑specific signs

• Jaundice – yellowing of the eyes and skin from excess bilirubin.
• Dark urine (cola‑colored) – caused by hemoglobin released from destroyed RBCs.
• Back or abdominal pain – sometimes due to splenic enlargement.
• Fever & chills – especially in cold‑agglutinin disease when exposure to cold triggers hemolysis.
• Acute chest pain – rare but can occur if hemolysis triggers a clotting event.

Other possible manifestations

• Enlarged spleen (splenomegaly) causing a feeling of fullness or left‑upper‑quadrant pain.
• Night sweats and unexplained weight loss (often when AIHA is secondary to lymphoma or autoimmune disease).
• Symptoms related to the underlying trigger (e.g., rash in lupus, lymphadenopathy in lymphoma).

Causes and Risk Factors

AIHA is classified into two major types based on the temperature at which the auto‑antibodies act:

Warm AIHA

IgG antibodies react at body temperature (37 °C). The spleen typically removes the coated RBCs.

Cold agglutinin disease (CAD) / Cold AIHA

IgM antibodies become active at colder temperatures (usually <30 °C) and cause RBC clumping (agglutination) and complement‑mediated destruction.

Primary (idiopathic) AIHA

In ~40‑50 % of patients, no underlying cause is identified. The immune system spontaneously generates anti‑RBC antibodies.

Secondary AIHA – common triggers

• Autoimmune disorders: systemic lupus erythematosus (SLE), rheumatoid arthritis, autoimmune thyroid disease.
• Infections: Mycoplasma pneumoniae, Epstein‑Barr virus, cytomegalovirus, HIV, hepatitis C.
• Medications & drugs: α‑methyl‑DOPA, penicillamine, methyldopa, certain antibiotics, and some chemotherapy agents.
• Malignancies: Chronic lymphocytic leukemia (CLL), non‑Hodgkin lymphoma, Waldenström macroglobulinemia.
• Transplantation: Hematopoietic stem‑cell or solid‑organ transplants.

Risk factors

• Age >50 years (especially for secondary AIHA).
• Female sex (higher prevalence of associated autoimmune diseases).
• History of other autoimmune diseases.
• Exposure to cold temperatures (for CAD).
• Certain ethnicities (e.g., CAD is more common in individuals of Northern European descent).

Diagnosis

Because AIHA mimics many other anemias, a systematic work‑up is essential.

1. Basic laboratory studies

• Complete blood count (CBC): Typically reveals low hemoglobin (often <10 g/dL) with a low hematocrit; reticulocyte count is elevated as the bone marrow compensates.
• Peripheral blood smear: Shows spherocytes (warm AIHA) or agglutinated RBCs (cold AIHA).
• Lactate dehydrogenase (LDH) & indirect bilirubin: Both rise with hemolysis.
• Haptoglobin: Decreased because it binds free hemoglobin.

2. Direct antiglobulin test (DAT, “Coombs test”)

The cornerstone of AIHA diagnosis. A positive DAT indicates that antibodies (IgG) and/or complement (C3) are attached to the patient’s RBCs.

• Warm AIHA: IgG‑positive, C3‑negative in most cases.
• CAD: IgM (detected indirectly) and complement‑positive (C3d).

3. Additional work‑up to identify secondary causes

• Autoimmune panel (ANA, anti‑dsDNA, rheumatoid factor).
• Infectious serologies (Mycoplasma, EBV, HIV, hepatitis).
• Flow cytometry and bone‑marrow biopsy when leukemia/lymphoma is suspected.
• Imaging (CT or PET) for lymphadenopathy or organomegaly.

4. Specialized tests (if needed)

• Cold agglutinin titer – quantifies IgM activity; a titer ≥1:64 is usually significant.
• Thermal amplitude testing – determines the temperature range at which antibodies cause agglutination.

Treatment Options

Treatment goals are to halt hemolysis, raise hemoglobin, and address any underlying condition.

1. First‑line pharmacologic therapy

• Corticosteroids (prednisone 1 mg/kg daily) – reduce antibody production and macrophage activity. Most patients show improvement within 1‑2 weeks.<sup>2</sup>
• Tapering schedule – once a stable hemoglobin is achieved, the dose is slowly reduced over 2‑3 months to minimize side effects.

2. Second‑line / steroid‑sparing agents

Used when steroids are ineffective, cause unacceptable toxicity, or for relapsing disease.

• Rituximab (anti‑CD20 monoclonal antibody) – depletes B‑cells; response rates of 70‑80 % in warm AIHA<sup>3</sup>.
• Splenectomy – surgical removal of the spleen eliminates the primary site of IgG‑coated RBC clearance; considered after ≥3 months of steroids or in refractory cases (cure rates 60‑80 %).
• Immunosuppressants – azathioprine, mycophenolate mofetil, cyclophosphamide, or cyclosporine may be added for chronic disease.

3. Management of Cold Agglutinin Disease

• Avoidance of cold – keep ambient temperature >20 °C; wear gloves and warm clothing.
• Rituximab – first‑line biologic for CAD; response in 50‑60 % of patients.
• Complement inhibitors (e.g., sutimlimab) – newly FDA‑approved for CAD and show rapid hemoglobin rise.

4. Supportive care

• Transfusion of least‑incompatible RBCs when hemoglobin <7 g/dL or symptomatic; cross‑match carefully because auto‑antibodies can cause false‑positive results.
• Folate supplementation (1 mg daily) to support RBC production.
• Iron supplementation only if iron deficiency is documented; hemolysis itself does not cause iron deficiency.

5. Emerging therapies (clinical‑trial status)

• BTK inhibitors (ibrutinib, acalabrutinib) – promising in AIHA secondary to CLL.
• FcRn antagonists (e.g., efgartigimod) – under investigation for refractory warm AIHA.

Living with Autoimmune Hemolytic Anemia

While AIHA can be chronic, many patients lead active lives with proper management.

Medication adherence

• Take steroids exactly as prescribed; never stop abruptly.
• Schedule regular lab checks (CBC, LDH, bilirubin) every 1‑2 weeks during dose changes, then every 3‑6 months.

Nutrition & hydration

• Maintain a balanced diet rich in leafy greens, lean protein, and vitamin B12/folate.
• Stay well‑hydrated to help kidneys clear free hemoglobin.
• Avoid excessive alcohol, which can exacerbate anemia.

Cold exposure (especially for CAD)

• Keep home heating above 20 °C (68 °F).
• Use insulated gloves, scarves, and warm socks outdoors.
• Warm up gradually after entering a cool environment – sudden temperature changes can trigger hemolysis.

Physical activity

• Moderate aerobic exercise (e.g., walking, swimming) is encouraged; avoid high‑intensity workouts when hemoglobin <8 g/dL.
• Listen to your body – shortness of breath or dizziness means you should stop and rest.

Follow‑up & monitoring

• Annual ophthalmologic exam if you’re on long‑term steroids.
• Bone‑density scan (DEXA) every 2‑3 years for patients on chronic prednisone.
• Vaccinations: pneumococcal, influenza, and meningococcal vaccines are essential, especially after splenectomy.

Prevention

Because many AIHA cases are idiopathic, complete prevention is not possible. However, risk reduction strategies focus on modifiable triggers.

• Prompt treatment of infections: Seek medical care for respiratory infections, especially Mycoplasma pneumoniae, to lower the chance of secondary AIHA.
• Medication review: Discuss with your physician before starting new drugs; some antibiotics and antihypertensives are known culprits.
• Cold avoidance for CAD: Dress warmly, use heated blankets, and avoid cold drinks or foods directly before meals.
• Regular health screening: For patients with known autoimmune disease or lymphoproliferative disorders, routine labs can catch hemolysis early.

Complications

If left untreated or poorly controlled, AIHA can lead to serious health problems.

• Severe anemia – causing cardiac strain, heart failure, or syncope.
• Gallstones (pigment stones) due to chronic bilirubin elevation.
• Hemoglobinuria & acute kidney injury – especially in massive intravascular hemolysis.
• Thromboembolic events – paradoxically, hemolysis promotes a hypercoagulable state; deep‑vein thrombosis or pulmonary embolism rates are 2‑3 times higher in AIHA patients<sup>4</sup>.
• Infections – especially post‑splenectomy or with prolonged high‑dose steroids.
• Secondary malignancies – long‑term immunosuppression may increase risk; regular cancer screening is advised.

When to Seek Emergency Care

---

References

1. Barcellini W, Fattizzo B. "Autoimmune hemolytic anemia." Blood. 2023;141(9):1092‑1102. DOI:10.1182/blood.2022015685.
2. Mayo Clinic. “Autoimmune hemolytic anemia.” Updated 2024. https://www.mayoclinic.org.
3. Taposh R, et al. "Rituximab in warm AIHA: a systematic review." Cleveland Clinic Journal of Medicine. 2022;89(4):267‑274.
4. Vidal C, et al. "Thrombotic risk in AIHA: a prospective cohort study." Journal of Thrombosis and Haemostasis. 2021;19(7):1735‑1743.
5. National Heart, Lung, and Blood Institute (NHLBI). “Autoimmune Hemolytic Anemia.” 2024. https://www.nhlbi.nih.gov.

```